There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.
Danish biotech Zealand Pharma is targeting the “next generation” of weight loss drugs as competitors pile into a market ...
Men, Baby Boomers, and postgraduate degree-holders were among those most likely to say they wouldn’t choose medication over ...
Mounjaro and Zepbound are now out of shortage. This should be good news—but because so many patients are taking compounded ...
It's part of a class of drugs known as GLP-1 receptor agonists, which also includes Ozempic, Wegovy and Zepbound."It ...
These drugs work similarly but differ in dosage and specific indications (uses). Research suggests that tirzepatide is more ...
Now that the Mounjaro and Zepbound shortage is over, Eli Lilly is going after the cottage industry selling “compounded” ...
The change will expand access to the diabetes and weight-loss drugs. But it will also complicate the future of compounded ...
Eli Lilly anticipates regulatory approval for its weight-loss drug Zepbound in Japan by mid-2025, boosting its global ...
Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...
PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...
Data readouts over the next six months could set expectations for how the highly lucrative market for weight loss therapies ...